

Composition

1 tablet contains 40 or 80 mg
[1,1'-biphenyl]-2-carboxylic acid, 4'-[1,4'-dimethyl-2'-propyl-
[2,6-bis(1H-benzimidazole)-1'-yl)methyl] (= telmisartan)

Excipients: povidone (K25), meglumine, sodium hydroxide, sorbitol (E420),
magnesium stearate

Pharmacological properties:

Pharmacodynamic properties:

Pharmacotherapeutic Group: Angiotensin II Antagonists, plain ATC Code:
C09CA07

Mechanism of action:

Telmisartan is an orally active and specific angiotensin II receptor (type AT₁)
antagonist. Telmisartan displaces angiotensin II with very high affinity from its
binding site at the AT₁ receptor subtype, which is responsible for the known
actions of angiotensin II. Telmisartan does not exhibit any partial agonist activity
at the AT₁ receptor. Telmisartan selectively binds the AT₁ receptor. The binding
is long-lasting. Telmisartan does not show affinity for other receptors, including
AT₂ and other less characterised AT receptors. The functional role of these
receptors is not known, nor is the effect of their possible overstimulation by
angiotensin II, whose levels are increased by telmisartan. Plasma aldosterone
levels are decreased by telmisartan. Telmisartan does not inhibit human plasma
renin or block ion channels. Telmisartan does not inhibit angiotensin converting
enzyme (kininase II), the enzyme which also degrades bradykinin. Therefore it is
not expected to potentiate bradykinin-mediated adverse effects.
In human, an 80 mg dose of telmisartan almost completely inhibits the angio-
tensin II evoked blood pressure increase. The inhibitory effect is maintained over
24 hours and still measurable up to 48 hours.

Clinical efficacy and safety:

Treatment of essential hypertension

After the first dose of telmisartan, the antihypertensive activity gradually
becomes evident within 3 hours. The maximum reduction in blood pressure
is generally attained 4 to 8 weeks after the start of treatment and is sustained
during long-term therapy.
The antihypertensive effect persists constantly over 24 hours after dosing and
includes the last 4 hours before the next dose as shown by ambulatory blood
pressure measurements. This is confirmed by trough to peak ratios consistently
above 80 % seen after doses of 40 and 80 mg of telmisartan in placebo
controlled clinical studies. There is an apparent trend to a dose relationship to
a time to recovery of baseline systolic blood pressure (SBP). In this respect data
concerning diastolic blood pressure (DBP) are inconsistent.

In patients with hypertension telmisartan reduces both systolic and diastolic
blood pressure without affecting pulse rate. The contribution of the medicinal
product's diuretic and natriuretic effect to its hypotensive activity has still to be
defined. The antihypertensive efficacy of telmisartan is comparable to that of
agents representative of other classes of antihypertensive medicinal products
(demonstrated in clinical trials comparing telmisartan to amlodipine, atenolol,
enalapril, hydrochlorothiazide, and lisinopril).
Upon abrupt cessation of treatment with telmisartan, blood pressure gradually
returns to pre-treatment values over a period of several days without evidence of
rebound hypertension.
The incidence of dry cough was significantly lower in patients treated with
telmisartan than in those given angiotensin converting enzyme inhibitors in
clinical trials directly comparing the two antihypertensive treatments.

Cardiovascular prevention

ONTARGET (ONgoing Telmisartan Alone and in Combination with Ramipril
Global Endpoint Trial) compared the effects of telmisartan, ramipril and the
combination of telmisartan and ramipril on cardiovascular outcomes in
25620 patients aged 55 years or older with a history of coronary artery disease,
stroke, Transient Ischemic Attack, peripheral arterial disease or type 2 diabetes
mellitus accompanied by evidence of end-organ damage, e.g. retinopathy,
left ventricular hypertrophy, macro- or microalbuminuria, which is a population
at risk for cardiovascular events.

Patients were randomized to one of the three following treatment groups:
telmisartan 80 mg (n = 8542), ramipril 10 mg (n = 8576), or the combination
of telmisartan 80 mg plus ramipril 10 mg (n = 8502), and followed for a mean
observation time of 4.5 years.

Telmisartan showed a similar effect to ramipril in reducing the primary
composite endpoint of cardiovascular death, non-fatal myocardial infarction,
non-fatal stroke, or hospitalization for congestive heart failure. The incidence
of the primary endpoint was similar in the telmisartan (16.7 %) and ramipril
(16.5 %) groups. The hazard ratio for telmisartan vs. ramipril was 1.01
(97.5 % CI 0.93–1.10, p (non-inferiority) = 0.0019 at a margin of 1.13).
The all-cause mortality rate was 11.6 % and 11.8 % among telmisartan and
ramipril treated patients, respectively.

Telmisartan was found to be similarly effective to ramipril in the pre-specified
secondary endpoint of cardiovascular death, non-fatal myocardial infarction,
and non-fatal stroke [0.99 (97.5 % CI 0.90–1.08), p (non-inferiority) = 0.0004],
the primary endpoint in the reference study HOPE (The Heart Outcomes
Prevention Evaluation Study), which had investigated the effect of ramipril
vs. placebo.

TRANSCEND randomized ACE-I intolerant patients with otherwise similar
inclusion criteria as ONTARGET to telmisartan 80 mg (n = 2954) or placebo
(n = 2972), both given on top of standard care. The mean duration of follow up
was 4 years and 8 months. No statistically significant difference in the incidence

of the primary composite endpoint (cardiovascular death, non-fatal myocardial
infarction, non-fatal stroke, or hospitalization for congestive heart failure)
was found [15.7 % in the telmisartan and 17.0 % in the placebo groups with
a hazard ratio of 0.92 (95 % CI 0.81–1.05, p = 0.22)]. There was evidence for
a benefit of telmisartan compared to placebo in the pre-specified secondary
composite endpoint of cardiovascular death, non-fatal myocardial infarction,
and non-fatal stroke [0.87 (95 % CI 0.76–1.00, p = 0.048)]. There was no
evidence for benefit on cardiovascular mortality (hazard ratio 1.03,
95 % CI 0.85–1.24).

Cough and angioedema were less frequently reported in patients treated with
telmisartan than in patients treated with ramipril, whereas hypotension was
more frequently reported with telmisartan.

Combining telmisartan with ramipril did not add further benefit over ramipril or
telmisartan alone. CV mortality and all cause mortality was numerically higher
with the combination. In addition, there was a significantly higher incidence
of hyperkalaemia, renal failure, hypotension and syncope in the combination
arm. Therefore the use of a combination of telmisartan and ramipril is not
recommended in this population.

In the „Prevention Regimen For Effectively avoiding Second Strokes“ (PROFESS)
trial in patients 50 years and older, who recently experienced stroke,
an increased incidence of sepsis was noted for telmisartan compared with
placebo, 0.70 % vs. 0.49 % [RR 1.43 (95 % confidence interval 1.00–2.06)].
The incidence of fatal sepsis cases was increased for patients taking telmisartan
(0.33 %) vs. patients taking placebo (0.16 %) [RR 2.07 (95 % confidence interval
1.14–3.76)]. The observed increased occurrence rate of sepsis associated with
the use of telmisartan may be either a chance finding or related to a mechanism
not currently known.

Pharmacokinetics

Absorption: Absorption of telmisartan is rapid although the amount absorbed
varies. The mean absolute bioavailability for telmisartan is about 50 %.
When telmisartan is taken with food, the reduction in the area under the plasma
concentration-time curve (AUC_{0-∞}) of telmisartan varies from approximately
6 % (40 mg dose) to approximately 19 % (160 mg dose). By 3 hours after
administration, plasma concentrations are similar whether telmisartan is taken
fasting or with food.

Linearity/non-linearity: The small reduction in AUC is not expected to cause a
reduction in the therapeutic efficacy.

There is no linear relationship between doses and plasma levels. C_{max} and to
a lesser extent AUC increase disproportionately at doses above 40 mg.

Distribution: Telmisartan is largely bound to plasma protein (> 99.5 %),
mainly albumin and alpha-1 acid glycoprotein. The mean steady state apparent
volume of distribution (V_{ss}) is approximately 500 L.

Metabolism: Telmisartan is metabolised by conjugation to the glucuronide of
the parent compound. No pharmacological activity has been shown for the
conjugate.

Elimination: Telmisartan is characterised by biexponential decay pharmaco-
kinetics with a terminal elimination half-life of >20 hours. The maximum
plasma concentration (C_{max}) and, to a smaller extent, the area under the plasma
concentration-time curve (AUC), increase disproportionately with dose.
There is no evidence of clinically relevant accumulation of telmisartan taken at
the recommended dose. Plasma concentrations were higher in females than in
males, without relevant influence on efficacy.
After oral (and intravenous) administration, telmisartan is nearly exclusively
excreted with the faeces, mainly as unchanged compound. Cumulative urinary
excretion is < 1 % of dose. Total plasma clearance (CL_{tot}) is high (approximately
1,000 ml/min) compared with hepatic blood flow (about 1,500 ml/min).

Special Populations

Gender effects: Differences in plasma concentrations were observed,
with C_{max} and AUC being approximately 3- and 2-fold higher, respectively,
in females compared to males.

Elderly patients: The pharmacokinetics of telmisartan do not differ between the
elderly and those younger than 65 years.

Patients with renal impairment: In patients with mild to moderate and severe
renal impairment, doubling of plasma concentrations was observed. However,
lower plasma concentrations were observed in patients with renal insufficiency
undergoing dialysis. Telmisartan is highly bound to plasma protein in renal-
insufficient patients and cannot be removed by dialysis. The elimination half-life
is not changed in patients with renal impairment.

Patients with hepatic impairment: Pharmacokinetic studies in patients with
hepatic impairment showed an increase in absolute bioavailability up to
nearly 100 %. The elimination half-life is not changed in patients with hepatic
impairment.

Indications

Hypertension

Treatment of essential hypertension in adults.

Cardiovascular prevention

Reduction of cardiovascular morbidity in patients with:

- Manifest atherothrombotic cardiovascular disease (history of coronary heart
disease or stroke, or peripheral arterial disease) or
- Type 2 diabetes mellitus with documented target organ damage

Contraindications

- Hypersensitivity to the active substance or to any of the excipients
(see Section Composition – excipients)

- Second and third trimesters of pregnancy (see sections Special warnings and precautions and pregnancy and lactation)
- Biliary obstructive disorders
- Severe hepatic impairment

Side effects

The overall incidence of adverse events reported with telmisartan (41.4 %) was usually comparable to placebo (43.9 %) in controlled trials in patients treated for hypertension. The incidence of adverse events was not dose related and showed no correlation with gender, age or race of the patients. The safety profile of telmisartan in patients treated for reduction of cardiovascular morbidity was consistent with that obtained in hypertensive patients. The adverse drug reactions listed below have been accumulated from controlled clinical trials in patients treated for hypertension and from post-marketing reports. The listing also takes into account serious adverse events and adverse events leading to discontinuation reported in three clinical long-term studies including 21642 patients treated with telmisartan for reduction of cardiovascular morbidity for up to six years.

Adverse reactions have been ranked under headings of frequency using the following convention:
very common (≥ 1/10); common (≥ 1/100 to < 1/10);
uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000);
very rare (< 1/10,000), not known (cannot be estimated from the available data).
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

System Organ Class / MedDRA Preferred Term	Frequency
Infections and infestations	
Upper respiratory tract infection including pharyngitis and sinusitis, urinary tract infection including cystitis	Uncommon
Sepsis including fatal outcome ¹	Not known
Blood and the lymphatic system disorders	
Anaemia	Uncommon
Thrombocytopenia	Rare
Eosinophilia	Not known
Immune system disorders	
Hypersensitivity	Rare
Anaphylactic reaction	Not known
Metabolism and nutrition disorders	
Hyperkalaemia	Uncommon
Psychiatric disorders	
Depression, insomnia	Uncommon
Anxiety	Rare
Nervous system disorders	
Syncope	Uncommon
Eye disorders	
Visual disturbance	Rare
Ear and labyrinth disorders	
Vertigo	Uncommon
Cardiac disorders	
Bradycardia	Uncommon
Tachycardia	Rare
Vascular disorders	
Hypotension ² , orthostatic hypotension	Uncommon
Respiratory, thoracic and mediastinal disorders	
Dyspnoea	Uncommon
Gastrointestinal disorders	
Abdominal pain, diarrhoea, dyspepsia, flatulence, Vomiting	Uncommon
Stomach discomfort, dry mouth	Rare
Hepato-biliary disorders	
Hepatic function abnormal/liver disorder	Rare
Skin and subcutaneous tissue disorders	
Hyperhidrosis, pruritus, rash	Uncommon
Erythema, angioedema, drug eruption, toxic skin eruption, eczema	Rare
Urticaria	Not known
Musculoskeletal and connective tissue disorders	
Myalgia, back pain (e.g. sciatica), muscle spasms	Uncommon
Arthralgia, pain in extremity	Rare
Tendon pain (tendonitis like symptoms)	Not known
Renal and urinary disorders	
Renal impairment including acute renal failure	Uncommon
General disorders and administration site conditions	
Chest pain, asthenia (weakness)	Uncommon
Influenza-like illness	Rare
Investigations	
Blood creatinine increased	Uncommon
Blood uric acid increased, hepatic enzyme increased, blood creatine phosphokinase increased, haemoglobin decreased	Rare

¹ In the PROfESS trial, an increased incidence of sepsis was observed with telmisartan compared with placebo. The event may be a chance finding or related to a mechanism currently not known (see section Pharmacodynamic properties).

² Reported as common in patients with controlled blood pressure who were treated with telmisartan for reduction of cardiovascular morbidity on top of standard care.

Special warnings and precautions

Pregnancy: Angiotensin II receptor antagonists should not be initiated during pregnancy. Unless continued angiotensin II receptor antagonist therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II receptor antagonists should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections Contraindications and pregnancy and lactation).

Hepatic impairment: MICARDIS is not to be given to patients with cholestasis, biliary obstructive disorders or severe hepatic impairment (see section Contraindications) since telmisartan is mostly eliminated with the bile. These patients can be expected to have reduced hepatic clearance for telmisartan. MICARDIS should be used only with caution in patients with mild to moderate hepatic impairment

Renovascular hypertension: There is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with medicinal products that affect the renin-angiotensin-aldosterone system.

Renal impairment and kidney transplantation: When MICARDIS is used in patients with impaired renal function, periodic monitoring of potassium and creatinine serum levels is recommended. There is no experience regarding the administration of MICARDIS in patients with recent kidney transplantation.

Intravascular hypovolaemia: Symptomatic hypotension, especially after the first dose of MICARDIS, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea, or vomiting. Such conditions should be corrected before the administration of MICARDIS. Volume and/or sodium depletion should be corrected prior to administration of MICARDIS.

Dual blockade of the renin-angiotensin-aldosterone system: As a consequence of inhibiting the renin-angiotensin-aldosterone system, hypotension, syncope, hyperkalaemia, and changes in renal function (including acute renal failure) have been reported in susceptible individuals, especially if combining medicinal products that affect this system. Dual blockade of the renin-angiotensin-aldosterone system (e.g. by adding an ACE-inhibitor to an angiotensin II receptor antagonist) is therefore not recommended in patients with already controlled blood pressure and should be limited to individually defined cases with close monitoring of renal function.

Other conditions with stimulation of the renin-angiotensin-aldosterone system
In patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with medicinal products that affect this system such as telmisartan has been associated with acute hypotension, hyperazotaemia, oliguria, or rarely acute renal failure (see section Side effects).

Primary aldosteronism: Patients with primary aldosteronism generally will not respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. Therefore, the use of telmisartan is not recommended.

Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy: As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.

Hyperkalaemia: The use of medicinal products that affect the renin-angiotensin-aldosterone system may cause hyperkalaemia.

In the elderly, in patients with renal insufficiency, in diabetic patients, in patients concomitantly treated with other medicinal products that may increase potassium levels, and/or in patients with intercurrent events, hyperkalaemia may be fatal.

Before considering the concomitant use of medicinal products that affect the renin-angiotensin-aldosterone system, the benefit risk ratio should be evaluated.

The main risk factors for hyperkalaemia to be considered are:

- Diabetes mellitus, renal impairment, age (>70 years)
- Combination with one or more other medicinal products that affect the renin-angiotensin-aldosterone system and/or potassium supplements. Medicinal products or therapeutic classes of medicinal products that may provoke hyperkalaemia are salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal anti-inflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim.
- Intercurrent events, in particular dehydration, acute cardiac decompensation, metabolic acidosis, worsening of renal function, sudden worsening of the renal condition (e.g. infectious diseases), cellular lysis (e.g. acute limb ischemia, rhabdomyolysis, extend trauma).

Close monitoring of serum potassium in at risk patients is recommended (see section Interactions). Sorbitol: This medicinal product contains sorbitol (E420). Patients with rare hereditary problems of fructose intolerance should not take MICARDIS. Ethnic differences: As observed for angiotensin converting enzyme inhibitors, telmisartan and the other angiotensin II receptor antagonists are apparently less effective in lowering blood pressure in black people than in non-blacks, possibly because of higher prevalence of low-renin states in the black hypertensive population. Other: As with any antihypertensive agent, excessive reduction of blood pressure in patients with ischaemic cardiopathy

or ischaemic cardiovascular disease could result in a myocardial infarction or stroke.

Interactions

Interaction studies have only been performed in adults.

As with other medicinal products acting on the renin-angiotensin-aldosterone system, telmisartan may provoke hyperkalaemia (see section Special warnings and precautions). The risk may increase in case of treatment combination with other medicinal products that may also provoke hyperkalaemia (salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal anti-inflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim).

The occurrence of hyperkalaemia depends on associated risk factors.

The risk is increased in case of the above-mentioned treatment combinations.

The risk is particularly high in combination with potassium sparing-diuretics, and when combined with salt substitutes containing potassium. A combination with ACE inhibitors or NSAIDs, for example, presents a lesser risk provided that precautions for use are strictly followed.

Concomitant use not recommended

Potassium sparing diuretics or potassium supplements:

Angiotensin II receptor antagonists such as telmisartan, attenuate diuretic induced potassium loss. Potassium sparing diuretics e.g. spirinolactone, eplerenone, triamterene, or amiloride, potassium supplements, or potassium-containing salt substitutes may lead to a significant increase in serum potassium. If concomitant use is indicated because of documented hypokalaemia they should be used with caution and with frequent monitoring of serum potassium.

Lithium:

Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors, and with angiotensin II receptor antagonists, including telmisartan. If use of the combination proves necessary, careful monitoring of serum lithium levels is recommended.

Concomitant use requiring caution

Non-steroidal anti-inflammatory medicinal products:

~~NSAIDs (i.e. acetylsalicylic acid at anti-inflammatory dosage regimen,~~

COX-2 inhibitors and non-selective NSAIDs) may reduce the antihypertensive effect of angiotensin II receptor antagonists.

In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function), the co-administration of angiotensin II receptor antagonists and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. Therefore, the combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy and periodically thereafter.

In one study the co-administration of telmisartan and ramipril led to an increase of up to 2.5 fold in the AUC₀₋₂₄ and C_{max} of ramipril and ramiprilat.

The clinical relevance of this observation is not known.

Diuretics (thiazide or loop diuretics):

Prior treatment with high dose diuretics such as furosemide (loop diuretic) and hydrochlorothiazide (thiazide diuretic) may result in volume depletion and in a risk of hypotension when initiating therapy with telmisartan.

To be taken into account with concomitant use

Other antihypertensive agents:

The blood pressure lowering effect of telmisartan can be increased by concomitant use of other antihypertensive medicinal products.

Based on their pharmacological properties it can be expected that the following medicinal products may potentiate the hypotensive effects of all antihypertensives including telmisartan: Baclofen, amifostine. Furthermore, orthostatic hypotension may be aggravated by alcohol, barbiturates, narcotics or antidepressants.

Corticosteroids (systemic route):

Reduction of the antihypertensive effect.

Pregnancy and lactation

Pregnancy:

The use of angiotensin II receptor antagonists is not recommended during the first trimester of pregnancy (see section Special warnings and precautions). The use of angiotensin II receptor antagonists is contraindicated during the second and third trimesters of pregnancy (see sections Contraindications and Special warnings and precautions).

There are no adequate data from the use of MICARDIS in pregnant women. Studies in animals have shown reproductive toxicity.

Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with angiotensin II receptor antagonists, similar risks may exist for this class of drugs. Unless continued angiotensin II receptor antagonist therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II receptor antagonists should be stopped immediately, and, if appropriate, alternative therapy should be started.

Exposure to angiotensin II receptor antagonist therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia).

Should exposure to angiotensin II receptor antagonists have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.

Infants whose mothers have taken angiotensin II receptor antagonists should be closely observed for hypotension (see sections Contraindications and Special warnings and precautions).

Lactation:

Because no information is available regarding the use of MICARDIS during breast-feeding, MICARDIS is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.

Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. However, when driving vehicles or operating machinery it should be taken into account that dizziness or drowsiness may occasionally occur when taking antihypertensive therapy.

Dosage and administration

Treatment of essential hypertension:

The usually effective dose is 40 mg once daily. Some patients may already benefit at a daily dose of 20 mg. In cases where the target blood pressure is not achieved, the dose of telmisartan can be increased to a maximum of 80 mg once daily. Alternatively, telmisartan may be used in combination with thiazide-type diuretics such as hydrochlorothiazide, which has been shown to have an additive blood pressure lowering effect with telmisartan. When considering raising the dose, it must be borne in mind that the maximum antihypertensive effect is generally attained four to eight weeks after the start of treatment (see section Pharmacodynamic properties).

Cardiovascular prevention

The recommended dose is 80 mg once daily. It is not known whether doses lower than 80 mg of telmisartan are effective in reducing cardiovascular morbidity.

When initiating telmisartan therapy for the reduction of cardiovascular morbidity, close monitoring of blood pressure is recommended, and if appropriate adjustment of medications that lower blood pressure may be necessary.

Telmisartan may be taken with or without food

Special patient populations:

Renal impairment: No posology adjustment is required for patients with mild to moderate renal impairment. Limited experience is available in patients with severe renal impairment or haemodialysis.

A lower starting dose of 20 mg is recommended in these patients (see section Special warnings and precautions).

Hepatic impairment: In patients with mild to moderate hepatic impairment, the posology should not exceed 40 mg once daily (see section Special warnings and precautions).

Elderly: No dose adjustment is necessary for elderly patients.

Paediatric patients: MICARDIS is not recommended for use in children below 18 years due to a lack of data on safety and efficacy.

Overdose

There is limited information available with regard to overdose in humans.

Symptoms: The most prominent manifestations of telmisartan overdose were hypotension and tachycardia; bradycardia, dizziness, increase in serum creatinine, and acute renal failure have also been reported.

Treatment: Telmisartan is not removed by haemodialysis. The patient should be closely monitored, and the treatment should be symptomatic and supportive. Management depends on the time since ingestion and the severity of the symptoms. Suggested measures include induction of emesis and/or gastric lavage. Activated charcoal may be useful in the treatment of overdose. Serum electrolytes and creatinine should be monitored frequently. If hypotension occurs, the patient should be placed in a supine position, with salt and volume replacement given quickly.

Storage instructions

Store in the original package in order to protect from moisture.

Store below 30°C

Availability

Tablets of 40 and 80 mg

Date of package insert: (SPC) November 2009

Manufactured by

Boehringer Ingelheim Pharma GmbH & Co. KG
for **Boehringer Ingelheim International GmbH**
Ingelheim am Rhein
Germany

This is a medicament

Medicament is a product which affects your health, and its consumption contrary to instructions is dangerous for you.

Follow strictly the doctor's prescription, the method of use and the instructions of the pharmacist who sold the medicament

The doctors and the pharmacist are experts in medicine, its benefits and risks.

Do not by yourself interrupt the period of treatment prescribed for you.

Do not repeat the same prescription without consulting your doctor.

Keep medicament out of reach of children!

Council of Arab Health Ministers – Union of Arab Pharmacists